Ichizo Tsujino

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2489049/publications.pdf

Version: 2024-02-01

66 papers	2,170 citations	304602 22 h-index	223716 46 g-index
67 all docs	67 docs citations	67 times ranked	2511 citing authors

#	Article	IF	Citations
1	Association Between the Development of Thrombosis and Worsening of Disease Severity in Patients With Moderate COVID-19 on Admissionã€€â€• From the CLOT-COVID Study â€•. Circulation Journal, 2023, 87, 448-455.	0.7	3
2	Selexipag for the treatment of chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2022, 60, 2101694.	3.1	26
3	Determinants of altered left ventricular suction in pre-capillary pulmonary hypertension. European Heart Journal Cardiovascular Imaging, 2022, 23, 1399-1406.	0.5	2
4	D-Dimer Values and Venous Thromboembolism in Patients With COVID-19 in Japanã€€â€• From the CLOT-COVID Study â€•. Circulation Reports, 2022, , .	0.4	4
5	Accuracy of Swanâ€'Ganz catheterizationâ€based assessment of right ventricular function: Validation study using highâ€fidelity micromanometryâ€derived values as reference. Pulmonary Circulation, 2022, 12, e12078.	0.8	3
6	Phorbol 12-myristate 13-acetate stimulation under hypoxia induces nuclear swelling with DNA outflow but not extracellular trap formation of neutrophils. Experimental and Molecular Pathology, 2022, 125, 104754.	0.9	3
7	The current status of thrombosis and anticoagulation therapy in patients with COVID-19 in Japan: From the CLOT-COVID study. Journal of Cardiology, 2022, 80, 285-291.	0.8	18
8	Influence of sex on development of thrombosis in patients with COVID-19: From the CLOT-COVID study. Thrombosis Research, 2022, 213, 173-178.	0.8	12
9	Underdiagnosis of cardiac sarcoidosis by ECG and echocardiography in cases of extracardiac sarcoidosis. ERJ Open Research, 2022, 8, 00516-2021.	1.1	7
10	Therapeutic-Dose vs. Prophylactic-Dose Anticoagulation Therapy for Critically Ill Patients With COVID-19 in a Practice-Based Observational Study. Circulation Journal, 2022, 86, 1137-1142.	0.7	4
11	The rate of myocardial perfusion recovery after steroid therapy and its implication for cardiac events in cardiac sarcoidosis and primarily preserved left ventricular ejection fraction. Journal of Nuclear Cardiology, 2021, 28, 1745-1756.	1.4	9
12	18F-FMISO PET/CT detects hypoxic lesions of cardiac and extra-cardiac involvement in patients with sarcoidosis. Journal of Nuclear Cardiology, 2021, 28, 2141-2148.	1.4	23
13	Prognostic value of phase analysis on gated single photon emission computed tomography in patients with cardiac sarcoidosis. Journal of Nuclear Cardiology, 2021, 28, 128-136.	1.4	9
14	Improvements in French risk stratification score were correlated with reductions in mean pulmonary artery pressure in pulmonary arterial hypertension: a subanalysis of the Japan Pulmonary Hypertension Registry (JAPHR). BMC Pulmonary Medicine, 2021, 21, 28.	0.8	2
15	Multi-Institutional Prospective Cohort Study of Patients With Pulmonary Hypertension Associated With Respiratory Diseases. Circulation Journal, 2021, 85, 333-342.	0.7	10
16	Right ventricular pressureâ€"volume loop produced with simultaneous application of threeâ€dimensional echocardiography and highâ€fidelity micromanometry in a patient with pulmonary arterial hypertension. Echocardiography, 2021, 38, 805-807.	0.3	1
17	Incidence and Clinical Features of Venous Thromboembolism in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) in Japan. Circulation Journal, 2021, 85, 2208-2214.	0.7	30
18	Right ventricular function as assessed by cardiac magnetic resonance imagingâ€derived strain parameters compared to highâ€fidelity micromanometer catheter measurements. Pulmonary Circulation, 2021, 11, 1-10.	0.8	4

#	Article	IF	Citations
19	The assessment of left heart disease in patients with systemic sclerosis and pulmonary hypertension. Clinical and Experimental Rheumatology, 2021, 39 Suppl 131, 103-110.	0.4	0
20	The assessment of left heart disease in patients with systemic sclerosis and pulmonary hypertension. Clinical and Experimental Rheumatology, 2021, 39, 103-110.	0.4	0
21	A histopathological report of a 16-year-old male with peripheral pulmonary artery stenosis and Moyamoya disease with a homozygous RNF213 mutation. Respiratory Medicine Case Reports, 2020, 29, 100977.	0.2	5
22	Right ventriculoâ€“pulmonary arterial uncoupling and poor outcomes in pulmonary arterial hypertension. Pulmonary Circulation, 2020, 10, 1-11.	0.8	5
23	Pulmonary capillary hemangiomatosis-predominant vasculopathy in a patient with rheumatoid arthritis-associated interstitial lung disease: An autopsy report. Respiratory Medicine Case Reports, 2020, 31, 101215.	0.2	0
24	Psychometric Validation of a Japanese Version of the emPHasis-10 Questionnaire, a Patient-Reported Outcome Measure for Pulmonary Hypertensionã€€â€• Multicenter Study in Japan â€•. Circulation Reports, 2020, 2, 255-259.	0.4	5
25	Right ventricular dimension index by cardiac magnetic resonance for prognostication in connective tissue diseases and pulmonary hypertension. Rheumatology, 2019, 59, 622-633.	0.9	2
26	Reduced diffusing capacity for carbon monoxide predicts borderline pulmonary arterial pressure in patients with systemic sclerosis. Rheumatology International, 2019, 39, 1883-1887.	1.5	5
27	Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017). Circulation Journal, 2019, 83, 842-945.	0.7	132
28	Chinese herbal medicine Qing-Dai-induced pulmonary arterial hypertension in a patient with ulcerative colitis: A case report and experimental investigation. Respiratory Medicine Case Reports, 2019, 26, 265-269.	0.2	8
29	Cardiac sarcoidosis classification with deep convolutional neural network-based features using polar maps. Computers in Biology and Medicine, 2019, 104, 81-86.	3.9	36
30	Use of 18F-FDG PET/CT texture analysis to diagnose cardiac sarcoidosis. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1240-1247.	3.3	36
31	Amelioration of right ventricular systolic function and stiffness in a patient with idiopathic pulmonary arterial hypertension treated with oral triple combination therapy. Pulmonary Circulation, 2018, 8, 1-5.	0.8	4
32	Which is the proper reference tissue for measuring the change in FDG PET metabolic volume of cardiac sarcoidosis before and after steroid therapy?. EJNMMI Research, 2018, 8, 94.	1.1	15
33	Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage. Internal Medicine, 2018, 57, 1769-1772.	0.3	2
34	Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: A systematic review. Respiratory Investigation, 2018, 56, 332-341.	0.9	42
35	Successful treatment of tocilizumab-resistant large vessel pulmonary arteritis with infliximab. Immunological Medicine, 2018, 41, 39-42.	1.4	5
36	Efficient detection of pulmonary arterial hypertension using serum haptoglobin level and cardiac MRI in patients with connective tissue diseases: a pilot study. Clinical and Experimental Rheumatology, 2018, 36, 345-346.	0.4	1

#	Article	IF	Citations
37	Representative Chest Auscultation Findings in Pulmonary Hypertension: Phonocardiograms and Sound Clips. Annals of the American Thoracic Society, 2017, 14, e1-e3.	1.5	2
38	Replacement myocardial fibrosis at the site of late gadolinium enhancement on magnetic resonance imaging in a patient with diffuse cutaneous systemic sclerosis: An autopsy report. Journal of Cardiology Cases, 2017, 16, 48-51.	0.2	3
39	Performance of computed tomography-derived pulmonary vasculature metrics in the diagnosis and haemodynamic assessment of pulmonary arterial hypertension. European Journal of Radiology, 2017, 96, 31-38.	1.2	14
40	Accuracy of echocardiographic indices for serial monitoring of right ventricular systolic function in patients with precapillary pulmonary hypertension. PLoS ONE, 2017, 12, e0187806.	1.1	7
41	Clinical Application of ¹⁸F-fluorodeoxyglucose PET and LGE CMR in Cardiac Sarcoidosis. Annals of Nuclear Cardiology, 2017, 3, 125-130.	0.0	5
42	The Effects of Pulmonary Vasodilating Agents on Right Ventricular Parameters in Severe Group 3ÂPulmonary Hypertension: A Pilot Study. Pulmonary Circulation, 2016, 6, 524-531.	0.8	6
43	Comparison of 18F-fluorodeoxyglucose positron emission tomography (FDG PET) and cardiac magnetic resonance (CMR) in corticosteroid-naive patients with conduction system disease due to cardiac sarcoidosis. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 259-269.	3.3	73
44	Associations among the plasma amino acid profile, obesity, and glucose metabolism in Japanese adults with normal glucose tolerance. Nutrition and Metabolism, 2016, 13, 5.	1.3	131
45	The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial 18F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis. Journal of Nuclear Cardiology, 2016, 23, 244-252.	1.4	142
46	Multiâ€institutional retrospective cohort study of patients with severe pulmonary hypertension associated with respiratory diseases. Respirology, 2015, 20, 805-812.	1.3	38
47	Right atrial volume and reservoir function are novel independent predictors of clinical worsening in patients with pulmonary hypertension. Journal of Heart and Lung Transplantation, 2015, 34, 414-423.	0.3	41
48	Current trends in the management of pulmonary hypertension associated with respiratory disease in institutions approved by the Japanese Respiratory Society. Respiratory Investigation, 2014, 52, 167-172.	0.9	6
49	Right ventricular 18F-FDG uptake is an important indicator for cardiac involvement in patients with suspected cardiac sarcoidosis. Annals of Nuclear Medicine, 2014, 28, 656-663.	1.2	40
50	Hemodynamic effects of ambrisentan-tadalafil combination therapy on progressive portopulmonary hypertension. World Journal of Hepatology, 2014, 6, 825.	0.8	5
51	Elevated 18F-fluorodeoxyglucose uptake in the interventricular septum is associated with atrioventricular block in patients with suspected cardiac involvement sarcoidosis. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1558-1566.	3.3	50
52	Four cases with group 3 out-of-proportion pulmonary hypertension with a favorable response to vasodilators. Respiratory Medicine Case Reports, 2013, 9, 4-7.	0.2	4
53	Simple prediction of right ventricular ejection fraction using tricuspid annular plane systolic excursion in pulmonary hypertension. International Journal of Cardiovascular Imaging, 2013, 29, 1799-1805.	0.7	31
54	Right atrial volume and phasic function in pulmonary hypertension. International Journal of Cardiology, 2013, 168, 420-426.	0.8	45

#	Article	IF	Citations
55	Broad and heterogeneous vasculopathy in pulmonary fibrosis and emphysema with pulmonary hypertension. Respirology Case Reports, 2013, 1, 10-13.	0.3	20
56	Paradoxical Interventricular Septal Motion as a Major Determinant of Late Gadolinium Enhancement in Ventricular Insertion Points in Pulmonary Hypertension. PLoS ONE, 2013, 8, e66724.	1.1	30
57	Validation Study on the Accuracy of Echocardiographic Measurements of Right Ventricular Systolic Function in Pulmonary Hypertension. Journal of the American Society of Echocardiography, 2012, 25, 280-286.	1.2	125
58	Early Detection of Cardiac Sarcoid Lesions with 18F-fluoro-2-deoxyglucose Positron Emission Tomography. Internal Medicine, 2011, 50, 1207-1209.	0.3	22
59	18F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1773-1783.	3.3	124
60	Enhanced computed tomography unveiling the underlying cause of pulmonary hypertension. International Journal of Cardiovascular Imaging, 2010, 26, 257-258.	0.7	0
61	Imaging of Cardiac Sarcoid Lesions Using Fasting Cardiac ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography: An Autopsy Case. Circulation, 2010, 122, 535-536.	1.6	44
62	Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 933-941.	3.3	301
63	Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosisâ€. European Heart Journal, 2005, 26, 1538-1543.	1.0	360
64	Combination of 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in assessing cardiac sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2005, 22, 234-5.	0.2	22
65	A case of idiopathic constrictive bronchiolitis in a middleâ€aged male smoker. Respirology, 2000, 5, 305-307.	1.3	4
66	Measurement of exhaled nitric oxide concentration using nasal continuous negative pressure. Respirology, 1999, 4, 155-159.	1.3	1